KR850000530A - 루신 유도체의 제조방법 - Google Patents

루신 유도체의 제조방법 Download PDF

Info

Publication number
KR850000530A
KR850000530A KR1019840003509A KR840003509A KR850000530A KR 850000530 A KR850000530 A KR 850000530A KR 1019840003509 A KR1019840003509 A KR 1019840003509A KR 840003509 A KR840003509 A KR 840003509A KR 850000530 A KR850000530 A KR 850000530A
Authority
KR
South Korea
Prior art keywords
formula
compound
formamido
hexyl
hydroxy
Prior art date
Application number
KR1019840003509A
Other languages
English (en)
Other versions
KR920002314B1 (ko
Inventor
하트바리(외 4) 파울
Original Assignee
진 야크궤스오가이, 마인라트 쉬미트
에프. 호프만-라롯슈앤드 캄파니아크티엔 게젤샤프트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=4255488&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR850000530(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 진 야크궤스오가이, 마인라트 쉬미트, 에프. 호프만-라롯슈앤드 캄파니아크티엔 게젤샤프트 filed Critical 진 야크궤스오가이, 마인라트 쉬미트
Publication of KR850000530A publication Critical patent/KR850000530A/ko
Application granted granted Critical
Publication of KR920002314B1 publication Critical patent/KR920002314B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P13/00—Preparation of nitrogen-containing organic compounds
    • C12P13/04—Alpha- or beta- amino acids
    • C12P13/06—Alanine; Leucine; Isoleucine; Serine; Homoserine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/02—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D305/10—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having one or more double bonds between ring members or between ring members and non-ring members
    • C07D305/12—Beta-lactones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/02—Oxygen as only ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/465—Streptomyces
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/886—Streptomyces

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Epoxy Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

내용 없음.

Description

루신 유도체의 제조방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (4)

  1. 구조식(Ia)의 화합물을 생산하는 미생물 종인 스트렙토미세스 토시트리시니(streutomces toxytricini)를 적합한 탄소 및 질소원, 및 무기염류를 함유한 수성 배지중에서 호기적으로 배양하여 생성된 구조식(Ia)의 화합물을 배양육즙으로 부터 분리하여 구조식(Ia)의 (2s,3s,5s,7z,10z)-5-[(s)-2-포름아미도-4-메틸-발레릴옥시]-2-헥실-3-하이드록시-7,10-헥사-데카디에노산 락톤을 제조하거나; 구조식(Ia)의 화합물을 수소화시켜 구조식(Ib)의 (2s,3s,5s)-5-[(s)-2-포름아미도-4-메틸-발레링옥시]-2-헥실-3-하이드록시-헥사데카노산 락톤을 제조함을 특징으로하여, 일반식(I)의 화합물을 제조하는 방법.
    상기식에서,
    A는그룹 또는-(CH2)5-이다.
  2. 제1항에 있어서, 미생물이 구조식(Ia)의 화합물을 생산하는 스트렙토미세스톡시트리시니 NRRL 15443 또는 이의 2차 배양물, 변종 또는 돌연변이체인 방법.
  3. 제2항에 있어서, (2s,3s,5s,7z,10z)-5-[(s)-2-포름아미도 -4-메틸-발레릴-옥시]-2-헥실-3-하이드록시-7,10-헥사데카-디에노산 락톤을 제조하는 방법.
  4. 제1항에 있어서, (2s,3s,5s)-5-[(s)-2-포름아미도-4-메틸-발레릴옥시]-2-헥실-3-하이드록시-헥사데카노산 락톤을 제조하는 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019840003509A 1983-06-22 1984-06-21 루신 유도체의 제조방법 KR920002314B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CH341583 1983-06-22
CH3415/83 1983-06-22
CH3415 1983-06-22

Publications (2)

Publication Number Publication Date
KR850000530A true KR850000530A (ko) 1985-02-27
KR920002314B1 KR920002314B1 (ko) 1992-03-21

Family

ID=4255488

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019840003509A KR920002314B1 (ko) 1983-06-22 1984-06-21 루신 유도체의 제조방법

Country Status (26)

Country Link
US (1) US4598089A (ko)
EP (1) EP0129748B1 (ko)
JP (1) JPS6013777A (ko)
KR (1) KR920002314B1 (ko)
AT (1) ATE30025T1 (ko)
AU (1) AU572851B2 (ko)
BG (1) BG60766B2 (ko)
CA (1) CA1247547A (ko)
DE (2) DE3466538D1 (ko)
DK (1) DK160496C (ko)
ES (1) ES533557A0 (ko)
FI (1) FI78694C (ko)
GR (1) GR82120B (ko)
HU (1) HU193579B (ko)
IE (1) IE57761B1 (ko)
IL (1) IL72122A (ko)
LU (1) LU90302I2 (ko)
LV (1) LV5747B4 (ko)
MC (1) MC1602A1 (ko)
MX (1) MX9203633A (ko)
NL (1) NL980029I2 (ko)
NO (2) NO159941C (ko)
NZ (1) NZ208521A (ko)
PH (1) PH19704A (ko)
PT (1) PT78777B (ko)
ZA (1) ZA844558B (ko)

Families Citing this family (228)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1270837A (en) * 1984-12-21 1990-06-26 Hoffmann-La Roche Limited Oxetanones
CA1328881C (en) * 1984-12-21 1994-04-26 Pierre Barbier Process for the manufacture of oxetanones
ZA859574B (en) * 1984-12-21 1986-08-27 Hoffmann La Roche Process for the manufacture of oxetanones
JPH0618793Y2 (ja) * 1986-06-13 1994-05-18 パイオニア株式会社 作業台
US4816477A (en) * 1987-05-26 1989-03-28 Merck & Co., Inc. Antihypercholesterolemic β-lactones
US4806564A (en) * 1987-05-26 1989-02-21 Merck & Co., Inc. Antihypercholesterolemic beta-lactones
US5484777A (en) * 1989-04-20 1996-01-16 Lange, Iii; Louis G. Pancreatic cholesterol esterase inhibitor
US5017565A (en) * 1989-04-20 1991-05-21 Lange Iii Louis G Use of sulfated polysaccharides to inhibit pancreatic cholesterol esterase
US5063210A (en) * 1989-04-20 1991-11-05 Lange Iii Louis G Use of sulfated polysaccharides to decrease cholesterol and fatty acid absorption
JP2960947B2 (ja) * 1989-12-25 1999-10-12 日清製粉株式会社 脂質分解酵素阻害剤
US5376640A (en) * 1989-12-25 1994-12-27 Nisshin Flour Milling Co., Ltd. Lipolytic enzyme inhibitors
CA2098167C (en) * 1992-06-24 2006-12-19 Dorothea Isler Foodstuffs and feedstuffs containing a lipase inhibitor
TW381025B (en) * 1993-08-05 2000-02-01 Hoffmann La Roche Pharmaceutical composition containing a glucosidase inhibitor and a lipase inhibitor
US6642268B2 (en) 1994-09-13 2003-11-04 G.D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors
US6262277B1 (en) 1994-09-13 2001-07-17 G.D. Searle And Company Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
US6268392B1 (en) 1994-09-13 2001-07-31 G. D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors
MY116591A (en) * 1996-04-26 2004-02-28 Hoffmann La Roche Process for the production of lipstatin and tetrahydrolipstatin
US6004996A (en) * 1997-02-05 1999-12-21 Hoffman-La Roche Inc. Tetrahydrolipstatin containing compositions
EP1017408B1 (en) * 1997-02-05 2005-04-13 F. Hoffmann-La Roche Ag Use of tethrahydrolipstatin in the treatment of diabetes type ii
US7344713B1 (en) * 1997-07-07 2008-03-18 Pimentel Julio L Decreased fat absorption with an anti-lipase antibody
GB9727131D0 (en) * 1997-12-24 1998-02-25 Knoll Ag Therapeutic agents
US6299868B1 (en) 1999-07-14 2001-10-09 Geltex Pharmaceuticals, Inc. Fat-binding polymers
US6264937B1 (en) 1998-01-09 2001-07-24 Geltex Pharmaceuticals, Inc. Fat-binding polymers
US7048917B1 (en) 1998-01-09 2006-05-23 Genzyme Corporation Fat-binding polymers
PT1105122E (pt) 1998-08-14 2005-08-31 Hoffmann La Roche Composicoes farmaceuticas que contem inibidores de lipase
JP3761783B2 (ja) * 1998-08-14 2006-03-29 エフ．ホフマン−ラ ロシュ アーゲー リパーゼ阻害剤とキトサンを含む製薬学的組成物
US6489366B1 (en) 1998-12-23 2002-12-03 G. D. Searle, Llc Combinations of cholesteryl ester transfer protein inhibitors and nicotinic acid derivatives for cardiovascular indications
US6462091B1 (en) 1998-12-23 2002-10-08 G.D. Searle & Co. Combinations of cholesteryl ester transfer protein inhibitors and HMG coA reductase inhibitors for cardiovascular indications
JP2002533414A (ja) 1998-12-23 2002-10-08 ジー．ディー．サール エルエルシー 心臓血管に適用するための回腸胆汁酸輸送阻害剤および胆汁酸隔離剤の組み合わせ
IL143947A0 (en) 1998-12-23 2002-04-21 Searle Llc Combinations of ileal bile acid transport inhibitors and fibric acid derivatives for cardiovascular indications
ES2203239T3 (es) 1998-12-23 2004-04-01 G.D. Searle Llc Combinaciones de inhibidores de la proteina de transferencia de ester de colesterilo y de agentes secuestrantes de acidos biliares para indicaciones cardiovasculares.
AU776664B2 (en) 1998-12-23 2004-09-16 G.D. Searle Llc Combinations of cholesteryl ester transfer protein inhibitors and fibric acid derivatives for cardiovascular indications
NZ512536A (en) 1998-12-23 2003-11-28 G Combinations of ileal bile acid transport inhibitors and cholesteryl ester transfer protein inhibitors for cardiovascular indications
ATE228118T1 (de) * 1999-01-29 2002-12-15 Hoffmann La Roche Reinigung von lipstatin
MXPA02000492A (es) * 1999-07-14 2002-07-02 Geltex Pharma Inc Polimeros enlazantes de grasas, opcionalmente combinados con inhibidores de lipasas.
AR025587A1 (es) * 1999-09-13 2002-12-04 Hoffmann La Roche Formulaciones en dispersion que contienen inhibidores de lipasa
AR025609A1 (es) 1999-09-13 2002-12-04 Hoffmann La Roche Formulaciones lipidas solidas
EP1132389A1 (en) 2000-03-06 2001-09-12 Vernalis Research Limited New aza-indolyl derivatives for the treatment of obesity
US6794544B2 (en) 2000-03-10 2004-09-21 Pharmacia Corporation Method for the preparation of tetrahydrobenzothiepines
DE10021618A1 (de) * 2000-05-04 2001-11-15 Volker Helmstaedter Präparat für Darmerkrankungen und dessen Verwendung
EP1142572A1 (de) * 2000-04-04 2001-10-10 Volker Dr. Helmstädter Oxetanon-enthaltende Präparate zur Behandlung von Darmerkrankungen
EP1296656B1 (en) * 2000-06-27 2006-08-02 F. Hoffmann-La Roche Ag Method for preparing a composition
AU8969901A (en) * 2000-07-28 2002-02-13 Hoffmann La Roche New pharmaceutical composition
ATE293477T1 (de) * 2000-07-28 2005-05-15 Hoffmann La Roche Neue verwendung von lipase-inhibitoren
WO2002011719A2 (en) * 2000-08-09 2002-02-14 F. Hoffmann-La Roche Ag Lipase inhibitors for the treatment of dyspepsia
US6900226B2 (en) * 2000-09-06 2005-05-31 Hoffman-La Roche Inc. Neuropeptide Y antagonists
AU2167002A (en) 2000-10-16 2002-06-11 Hoffmann La Roche Indoline derivatives and their use as 5-ht2 receptor ligands
GB0030710D0 (en) * 2000-12-15 2001-01-31 Hoffmann La Roche Piperazine derivatives
BR0116605A (pt) 2000-12-27 2003-09-30 Hoffmann La Roche Composto, processo para a preparação de um composto, composição farmacêutica que compreende o mesmo, sua utilização e processo para o tratamento e profilaxia de distúrbios do sistema nervoso central, distúrbios cardiovasculares, distúrbios gastrintestinais e apnéia do sono
GB0106177D0 (en) * 2001-03-13 2001-05-02 Hoffmann La Roche Piperazine derivatives
US20030072804A1 (en) * 2001-03-19 2003-04-17 The Procter & Gamble Company Use of non-digestible polymeric foams to sequester ingested materials thereby inhibiting their absorption by the body
US20030091610A1 (en) * 2001-03-19 2003-05-15 The Procter & Gamble Company Use of non-digestible polymeric foams to sequester ingested materials thereby inhibiting their absorption by the body
DE60225274T2 (de) * 2001-05-21 2009-03-26 F. Hoffmann-La Roche Ag Chinolinderivate als liganden für den neuropeptid-y-rezeptor
US6730319B2 (en) 2001-06-06 2004-05-04 Hoffmann-La Roche Inc. Pharmaceutical compositions having depressed melting points
US20030027786A1 (en) 2001-06-06 2003-02-06 Karsten Maeder Lipase inhibiting composition
US7049345B2 (en) 2001-06-29 2006-05-23 Genzyme Corporation Fat-binding polymers
US7041280B2 (en) * 2001-06-29 2006-05-09 Genzyme Corporation Aryl boronate functionalized polymers for treating obesity
EP1446125B1 (en) 2001-08-30 2009-04-29 Alizyme Therapeutics Limited Thieno-(1,3)-oxazin-4-ones with lipase inhibiting activity
US6787558B2 (en) * 2001-09-28 2004-09-07 Hoffmann-La Roche Inc. Quinoline derivatives
US20190328679A1 (en) 2001-10-12 2019-10-31 Aquestive Therapeutics, Inc. Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US7357891B2 (en) 2001-10-12 2008-04-15 Monosol Rx, Llc Process for making an ingestible film
US8603514B2 (en) 2002-04-11 2013-12-10 Monosol Rx, Llc Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
US8900497B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for making a film having a substantially uniform distribution of components
US11207805B2 (en) 2001-10-12 2021-12-28 Aquestive Therapeutics, Inc. Process for manufacturing a resulting pharmaceutical film
US10285910B2 (en) 2001-10-12 2019-05-14 Aquestive Therapeutics, Inc. Sublingual and buccal film compositions
US20070281003A1 (en) 2001-10-12 2007-12-06 Fuisz Richard C Polymer-Based Films and Drug Delivery Systems Made Therefrom
US8900498B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for manufacturing a resulting multi-layer pharmaceutical film
US8765167B2 (en) 2001-10-12 2014-07-01 Monosol Rx, Llc Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US20110033542A1 (en) 2009-08-07 2011-02-10 Monosol Rx, Llc Sublingual and buccal film compositions
GB0125659D0 (en) * 2001-10-25 2001-12-19 Ssl Int Plc Spermicides
JP2005518347A (ja) 2001-11-02 2005-06-23 ジー．ディー． サール エルエルシー 頂端ナトリウム共依存性胆汁酸輸送（ａｓｂｔ）およびタウロコール酸塩取り込みの阻害剤としての新規一および二フッ化ベンゾチエピン化合物
US6734314B2 (en) 2001-12-04 2004-05-11 Biogal Gyogyszergyar Rt. Preparation of orlistat and orlistat crystalline forms
EP1458882A2 (en) 2001-12-04 2004-09-22 Biogal Gyogyszergyar Rt. A fermentation process for lipstatin and method of extracting lipstatin from a fermentation broth
KR20040068316A (ko) 2001-12-20 2004-07-30 오에스아이 파마슈티컬스, 인코포레이티드 판크레아 리파제 저해제 화합물, 그의 합성방법 및사용방법
MXPA04006255A (es) 2002-01-17 2004-09-27 Pharmacia Corp Compuestos novedosos de alquil/aril hidroxi o ceto tiepina como inhibidores del transporte del acido biliar codependiente del sodio apical y la captacion de taurocolato.
GB0202015D0 (en) * 2002-01-29 2002-03-13 Hoffmann La Roche Piperazine Derivatives
CA2473181A1 (en) * 2002-02-04 2003-08-14 F. Hoffmann-La Roche Ag Quinoline derivatives as npy antagonists
EP1480976B1 (en) * 2002-02-28 2007-09-19 F.Hoffmann-La Roche Ag Thiazole derivatives as npy receptor antagonists
AU2003226370A1 (en) * 2002-04-17 2003-11-03 The Burnham Institute Inhibition of fatty acid synthase by beta-lactones and other compounds for inhibition of cellular proliferation
US7728153B2 (en) * 2002-04-17 2010-06-01 The Burnham Institute For Medical Research Method for the asymmetric synthesis of beta-lactone compounds
ATE453390T1 (de) * 2002-04-26 2010-01-15 Hoffmann La Roche Pharmazeutische zusammensetzung enthaltend einen lipase - inhibitor und glucomannan
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
CN1665791A (zh) * 2002-07-05 2005-09-07 霍夫曼-拉罗奇有限公司 喹唑啉衍生物
RU2324685C2 (ru) * 2002-08-07 2008-05-20 Ф.Хоффманн-Ля Рош Аг Производные тиазола, способ их получения и применение, фармацевтическая композиция, обладающая свойствами антагонистов рецепторов npy
JP4286782B2 (ja) * 2002-09-12 2009-07-01 エフ．ホフマン−ラ ロシュ アーゲー 糖尿病の治療に有用な、ｐｐａｒアゴニストとしてのｎ−置換−１ｈ−インドール−５−プロピオン酸化合物
DE60323130D1 (de) * 2002-11-25 2008-10-02 Hoffmann La Roche Indolderivaten
US8372430B2 (en) 2002-12-17 2013-02-12 The Procter & Gamble Company Compositions, methods, and kits useful for the alleviation of gastrointestinal effects
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US20040178058A1 (en) * 2003-03-10 2004-09-16 Hsueh-Chung Chen Electro-chemical deposition apparatus and method of preventing cavities in an ECD copper film
EP1457206A1 (en) * 2003-03-13 2004-09-15 Fournier Laboratories Ireland Limited Combined use of a fibrate and orlistat for the treatment of obesity
CA2526730A1 (en) * 2003-05-30 2004-12-09 Ranbaxy Laboratories Limited Substituted pyrrole derivatives
WO2004113314A1 (en) * 2003-06-23 2004-12-29 Biocon Limited Novel boronate esters
GB0314967D0 (en) * 2003-06-26 2003-07-30 Hoffmann La Roche Piperazine derivatives
US20060025337A1 (en) * 2003-07-01 2006-02-02 President And Fellows Of Harvard College Sirtuin related therapeutics and diagnostics for neurodegenerative diseases
WO2005007639A1 (en) * 2003-07-17 2005-01-27 Biocon Limited Preparation of tetrahydrolipstatin by hydrogenation of lipstatin, solvent extraction and purification
DE602004019939D1 (de) * 2003-08-12 2009-04-23 Hoffmann La Roche Thiazolderivate als npy-antagonisten
MXPA06001570A (es) * 2003-08-12 2006-05-15 Hoffmann La Roche Antagonistas del receptor de neuropeptido y (npy) 2-amino-5-benzoiltiazol.
US20050239859A2 (en) * 2003-09-03 2005-10-27 Solvay Pharmaceuticals Gmbh Novel medical uses of 4,5-dihydro-1h-pyrazole derivatives having cb1- antagonistic activity
ATE547404T1 (de) 2003-09-22 2012-03-15 Msd Kk Piperidinderivate
US20050143441A1 (en) * 2003-10-27 2005-06-30 Jochen Antel Novel medical combination treatment of obesity involving 4,5-dihydro-1H-pyrazole derivatives having CB1-antagonistic activity
US20050124660A1 (en) * 2003-10-27 2005-06-09 Jochen Antel Novel medical uses of compounds showing CB1-antagonistic activity and combination treatment involving said compounds
EP2428516A1 (en) 2003-11-19 2012-03-14 Metabasis Therapeutics, Inc. Novel phosphorus-containing thyromimetics
CA2548671C (en) * 2003-12-29 2015-02-24 President And Fellows Of Harvard College Compositions for treating or preventing obesity and insulin resistance disorders
US8017634B2 (en) 2003-12-29 2011-09-13 President And Fellows Of Harvard College Compositions for treating obesity and insulin resistance disorders
PL209905B1 (pl) 2004-01-15 2011-11-30 Bringwell Internat Ab Preparat do leczenia otyłości i związanego z nią syndromu metabolicznego
WO2005067913A1 (ja) 2004-01-16 2005-07-28 Fuji Oil Company, Limited リパーゼ阻害剤
US7074822B2 (en) 2004-02-23 2006-07-11 Solvay Pharmaceuticals Gmbh Alkyl carbamate-substituted β-lactones, process for their preparation, and pharmaceutical compositions containing them
US20080125403A1 (en) 2004-04-02 2008-05-29 Merck & Co., Inc. Method of Treating Men with Metabolic and Anthropometric Disorders
EP3263118B1 (en) 2004-05-10 2019-09-25 University of Copenhagen Flaxseeds for body weight management
JP2008508190A (ja) * 2004-07-19 2008-03-21 ノボ ノルディスク アクティーゼルスカブ 肥満または肥満に関連する疾患および障害の治療におけるカプサイシン受容体の活性の阻害
WO2006045799A2 (en) 2004-10-25 2006-05-04 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising cb1 cannabinoid receptor antagonists and potassium channel openers for the treatment of diabetes mellitus type i, obesity and related conditions
KR20070084455A (ko) * 2004-11-23 2007-08-24 워너-램버트 캄파니 엘엘씨 지질혈증 치료용 ｈｍｇ ｃｏ-ａ 환원효소 억제제로서의7-(2ｈ-피라졸-3-일)-3,5-디히드록시-헵탄산 유도체
WO2006110809A2 (en) * 2005-04-12 2006-10-19 Elan Pharma International, Limited Nanoparticulate lipase inhibitor formulations
WO2006117304A1 (en) * 2005-05-03 2006-11-09 F. Hoffmann-La Roche Ag Tetracyclic azapyrazinoindolines as 5-ht2 ligands
NZ562766A (en) 2005-05-30 2011-03-31 Banyu Pharma Co Ltd Piperidine derivatives as histamine-H3 receptor antagonists
WO2006138418A2 (en) * 2005-06-14 2006-12-28 President And Fellows Of Harvard College Improvement of cognitive performance with sirtuin activators
US20070149466A1 (en) * 2005-07-07 2007-06-28 Michael Milburn Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders
JPWO2007018248A1 (ja) 2005-08-10 2009-02-19 萬有製薬株式会社 ピリドン化合物
JP2009504707A (ja) * 2005-08-18 2009-02-05 エフ．ホフマン−ラ ロシュ アーゲー Ｈ３受容体調節剤として有用なチアゾリルピペリジン誘導体
US7875633B2 (en) 2005-08-24 2011-01-25 Banyu Pharmaceutical Co., Ltd. Phenylpyridone derivative
JPWO2007029847A1 (ja) 2005-09-07 2009-03-19 萬有製薬株式会社 二環性芳香族置換ピリドン誘導体
US7355055B2 (en) * 2005-09-08 2008-04-08 Reliance Life Sciences Pvt. Ltd. Compounds for treatment of lipase-mediated diseases
BRPI0617621A2 (pt) 2005-10-21 2011-08-02 Novartis Ag combinação de compostos orgánicos
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
JPWO2007049798A1 (ja) 2005-10-27 2009-04-30 萬有製薬株式会社 新規ベンゾオキサチイン誘導体
SG166829A1 (en) * 2005-11-08 2010-12-29 Ranbaxy Lab Ltd Process for (3r, 5r)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt
NZ568292A (en) 2005-11-10 2011-08-26 Msd Kk Spiro[cyclohexane-1,1'-(3'H)-4'-azaisobenzofuran]-4-carboxamide derivatives
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
DE602006021626D1 (de) * 2005-11-30 2011-06-09 Hoffmann La Roche 1,1-dioxo-thiomorpholinyl-indolyl-methanon-derivate zur verwendung als h3-modulatoren
JP2009517434A (ja) * 2005-11-30 2009-04-30 エフ．ホフマン−ラ ロシュ アーゲー ５−置換インドール−２−カルボキサミド誘導体
ATE500244T1 (de) * 2005-11-30 2011-03-15 Hoffmann La Roche 1,5-substituierte indol-2-yl amidderivative
CA2631128A1 (en) * 2005-12-09 2007-06-14 F. Hoffmann-La Roche Ag Tricyclic amide derivatives useful for treating obesity
CN101326187A (zh) * 2005-12-15 2008-12-17 霍夫曼-拉罗奇有限公司 吡咯并[2,3-c]吡啶衍生物
CN101331131A (zh) * 2005-12-16 2008-12-24 霍夫曼-拉罗奇有限公司 用作H3受体调节剂的吡咯并[2,3-b]吡啶衍生物
SK22006A3 (sk) * 2006-01-03 2007-08-02 Biotika, A. S. Kmeň Streptomyces toxytricini produkujúci lipstatín a príprava lipstatínu s uvedeným kmeňom
US20080021092A1 (en) * 2006-01-06 2008-01-24 Deepak Murpani Stable pharmaceutical compositions of orlistat
CN101374825A (zh) * 2006-01-13 2009-02-25 霍夫曼-拉罗奇有限公司 环己基哌嗪基甲酮衍生物及它们作为组胺h3受体调节剂的应用
JP5031771B2 (ja) * 2006-01-23 2012-09-26 エフ．ホフマン−ラ ロシュ アーゲー Ｈ３受容体活性を有するシクロヘキシルスルホンアミド誘導体
AR059838A1 (es) * 2006-03-14 2008-04-30 Ranbaxy Lab Ltd Formulaciones para dosis estabilizantes de estatina
KR101252635B1 (ko) 2006-04-20 2013-04-10 (주)아모레퍼시픽 리파아제 저해제 및 친유성 오일흡수제를 포함하는 약학조성물 및 이로부터 제조된 경구 투여용 제제
US7432255B2 (en) * 2006-05-16 2008-10-07 Hoffmann-La Roche Inc. 1H-indol-5-yl-piperazin-1-yl-methanone derivatives
KR20090015098A (ko) * 2006-05-30 2009-02-11 에프. 호프만-라 로슈 아게 피페리디닐 피리미딘 유도체
BRPI0714361A2 (pt) * 2006-07-14 2013-03-26 Ranbaxy Lab Ltd polimorfo cristalino, composiÇço farmacÊutica contendo o mesmo, mÉtodo para sua preparaÇço e mÉtodo de tratamento
US7514433B2 (en) 2006-08-03 2009-04-07 Hoffmann-La Roche Inc. 1H-indole-6-yl-piperazin-1-yl-methanone derivatives
EP2072519A4 (en) 2006-09-28 2009-10-21 Banyu Pharma Co Ltd DIARYLKETIMINDERIVAT
TW200831497A (en) * 2006-10-12 2008-08-01 Epix Delaware Inc Carboxamide compounds and their use
ES2382009T3 (es) 2006-12-01 2012-06-04 Bristol-Myers Squibb Company Derivados de N-((3-bencil)-2,2-(bis-fenil-)-propan-1-amina como inhibidores de CETP para el tratamiento de aterosclerosis y enfermedades cardiovasculares
US20080146559A1 (en) 2006-12-08 2008-06-19 Li Chen 4,5,6,7-Tetrahydro-Thieno [2,3-C] Pyridine Derivatives
US20080200422A1 (en) * 2007-01-09 2008-08-21 Cavener Douglas R Methods for reduction of adipose tissue mass
CA2682727C (en) 2007-04-02 2016-03-22 Banyu Pharmaceutical Co., Ltd. Indoledione derivative
US20080249156A1 (en) * 2007-04-09 2008-10-09 Palepu Nageswara R Combinations of statins and anti-obesity agent and glitazones
US20080248115A1 (en) * 2007-04-09 2008-10-09 Palepu Nageswara R Combinations of statins and anti-obesity agent
CA2687964A1 (en) * 2007-06-01 2009-02-19 The Trustees Of Princeton University Treatment of viral infections by modulation of host cell metabolic pathways
EP2170930B3 (en) 2007-06-04 2013-10-02 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
KR101504777B1 (ko) * 2007-06-06 2015-03-20 랜박시 래보러터리스 리미티드 오르리스타트의 제조 방법
EP2625968A1 (en) 2007-09-12 2013-08-14 Københavns Universitet Composition and methods for increasing the suppression of hunger and reducing the digestibility of non-fat energy satiety
EA201070378A1 (ru) * 2007-09-17 2010-08-30 Др. Редди`С Лабораторис Лтд. Фармацевтические составы орлистата
WO2009044380A2 (en) 2007-10-05 2009-04-09 Ranbaxy Laboratories Limited Formulations containing orlistat particles having controlled particle size
US20100317642A1 (en) * 2007-10-15 2010-12-16 Inventis Dds Pvt Limited Pharmaceutical composition of orlistat
US8298583B2 (en) * 2007-10-19 2012-10-30 Monosol Rx, Llc Film delivery system for tetrahydrolipstatin
JP2011506466A (ja) 2007-12-11 2011-03-03 株式会社サイトパスファインダー カルボキサミド化合物ならびにケモカイン受容体アゴニストとしてのそれらの使用
US20090214682A1 (en) * 2008-02-22 2009-08-27 Heuer Marvin A Composition and methods for weight loss in a subject
CA2714617A1 (en) 2008-03-06 2009-09-11 Banyu Pharmaceutical Co., Ltd. Alkylaminopyridine derivative
JP2011515100A (ja) * 2008-03-26 2011-05-19 バイオコン リミテッド 消費脂肪酸に対して高い収率係数のリパーゼ阻害剤を得る改善された発酵プロセス
AU2009229860A1 (en) 2008-03-28 2009-10-01 Msd K.K. Diarylmethylamide derivative having antagonistic activity on melanin-concentrating hormone receptor
JP2011522828A (ja) 2008-06-04 2011-08-04 シナジー ファーマシューティカルズ インコーポレイテッド 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト
AU2009261248A1 (en) 2008-06-19 2009-12-23 Banyu Pharmaceutical Co., Ltd. Spirodiamine-diarylketoxime derivative
EP2141236A1 (en) * 2008-07-03 2010-01-06 KRKA, D.D., Novo Mesto Process for production of lipstatin and microorganisms therefore
AU2009270833B2 (en) 2008-07-16 2015-02-19 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
WO2010013595A1 (ja) 2008-07-30 2010-02-04 萬有製薬株式会社 ５員－５員又は５員－６員縮環シクロアルキルアミン誘導体
US20110300175A1 (en) 2008-10-03 2011-12-08 Sigma Alimentos, S.A. De C.V. Composition for promoting control of total and ldl cholesterol, and/or weight loss and/or thermogenesis
WO2010042499A1 (en) * 2008-10-06 2010-04-15 Banner Pharmacaps, Inc. Stable solutions of orlistat for pharmaceutical dosage forms
WO2010043592A1 (en) * 2008-10-15 2010-04-22 Revotar Biopharmaceuticals Ag Lipase inhibitors for use for the treatment of obesity
CN102264228A (zh) 2008-10-22 2011-11-30 默沙东公司 用于抗糖尿病药的新的环状苯并咪唑衍生物
AU2009309037A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2010093601A1 (en) 2009-02-10 2010-08-19 Metabasis Therapeutics, Inc. Novel sulfonic acid-containing thyromimetics, and methods for their use
US20120053172A1 (en) 2009-02-12 2012-03-01 Cooperatieve Mirzorg U.A. Use of a combination of diazoxide and metformin for treating obesity or obesity related disorders
US20100215635A1 (en) * 2009-02-23 2010-08-26 Zoltan Kiss Small molecules to induce weight loss or to reduce weight gain
EP2414830A2 (en) 2009-03-31 2012-02-08 Robert Zimmermann Modulation of adipose triglyceride lipase for prevention and treatment of cachexia, loss of weight and muscle atrophy and methods of screening therefor
WO2010112569A1 (en) 2009-03-31 2010-10-07 Robert Zimmermann Modulation of adipose triglyceride lipase for prevention and treatment of cachexia, loss of weight and muscle atrophy and methods of screening therefor
BRPI0901602B8 (pt) 2009-04-03 2021-05-25 Ems S/A formulação farmacêuticas
WO2011028309A1 (en) 2009-09-04 2011-03-10 University Of Toledo PROCESSES FOR PRODUCING OPTICALLY PURE β-LACTONES FROM ALDEHYDES AND COMPOSITIONS PRODUCED THEREBY
PT2496583E (pt) 2009-11-02 2015-01-14 Pfizer Derivados de dioxa-biciclo[3.2.1]octano-2,3,4-triol
UA107369C2 (en) 2010-02-01 2014-12-25 Lab Bago S A Pharmaceutical composition with anti-obesity activity comprising a premixture of pure orlistat and preparation process
US8524909B2 (en) 2010-02-02 2013-09-03 Hoffmann-La Roche Inc. Tetrahydro-pyran derivatives
AU2011218830B2 (en) 2010-02-25 2014-07-24 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US8450350B2 (en) 2010-05-05 2013-05-28 Infinity Pharmaceuticals, Inc. Triazoles as inhibitors of fatty acid synthase
EP3159331A1 (en) 2010-05-05 2017-04-26 Infinity Pharmaceuticals, Inc. Tetrazolones as inhibitors of fatty acid synthase
JP2013528172A (ja) 2010-05-21 2013-07-08 ファイザー・インク ２−フェニルベンゾイルアミド
DK2575768T3 (en) 2010-05-24 2018-03-12 Swedish Oat Fiber Ab Aqueous Dispersion Comprehensive Galactolipids and Procedures for their Preparation
EP2392327A1 (en) 2010-06-04 2011-12-07 Universitätsmedizin der Johannes Gutenberg-Universität Mainz Use of orlistat for the anti-parasitic treatment of a parasitic disease
KR20130041177A (ko) 2010-07-06 2013-04-24 아스트라제네카 아베 치료제 976
CN101885713B (zh) * 2010-07-19 2011-11-30 大邦(湖南)生物制药有限公司 一种毒三素链霉菌发酵液中分离提取利普司他汀的工艺
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
CN101948450B (zh) * 2010-10-13 2013-04-24 鲁南制药集团股份有限公司 一种生产制备奥利司他的方法
US9149959B2 (en) 2010-10-22 2015-10-06 Monosol Rx, Llc Manufacturing of small film strips
BR112013010157B1 (pt) 2010-11-08 2020-02-04 Albireo Ab iinibidores do ibat, seus usos, e composição e combinações farmacêuticas
AU2011326872C1 (en) 2010-11-08 2015-02-19 Albireo Ab A pharmaceutical combination comprising an IBAT inhibitor and a bile acid binder
PE20140859A1 (es) 2011-02-25 2014-07-25 Merck Sharp & Dohme Novedosos derivados de azabencimidazol ciclico utiles como agentes antidiabeticos
WO2012120414A2 (en) 2011-03-04 2012-09-13 Pfizer Inc. Edn3-like peptides and uses thereof
UY34194A (es) 2011-07-15 2013-02-28 Astrazeneca Ab ?(3-(4-(espiroheterocíclico)metil)fenoxi)azetidin-1-il)(5-(fenil)-1,3,4-oxadiazol-2-il)metanona en el tratamiento de la obesidad?
CN102304105B (zh) * 2011-07-15 2013-07-10 鲁南新时代生物技术有限公司 一种制备高纯度奥利司他的方法
CN103030613B (zh) * 2011-09-29 2014-11-12 北大方正集团有限公司 一种利普司他汀的提纯方法
JP2013249293A (ja) * 2012-06-04 2013-12-12 Kao Corp リパーゼ活性阻害剤、抗真菌剤、及びフケ抑制剤
JP2015525782A (ja) 2012-08-02 2015-09-07 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 抗糖尿病性三環式化合物
WO2014060445A1 (en) 2012-10-19 2014-04-24 Akzo Nobel Chemicals International B.V. Method for preparing high purity orlistat
CN102936234B (zh) * 2012-11-15 2015-04-01 江苏阿尔法药业有限公司 一种制备脂肪酶抑制剂奥利司他的方法
CN102993134B (zh) * 2012-12-31 2015-08-05 鲁南新时代生物技术有限公司 一种利普司他汀的提纯方法
EP2958562A4 (en) 2013-02-22 2016-08-10 Merck Sharp & Dohme BICYCLIC ANTIDIABETIC COMPOUNDS
US9650375B2 (en) 2013-03-14 2017-05-16 Merck Sharp & Dohme Corp. Indole derivatives useful as anti-diabetic agents
WO2014151206A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
CA2905435A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
JP2016516804A (ja) 2013-04-17 2016-06-09 ファイザー・インク 心血管疾患を治療するためのｎ−ピペリジン−３−イルベンズアミド誘導体
EP3004138B1 (en) 2013-06-05 2024-03-13 Bausch Health Ireland Limited Ultra-pure agonists of guanylate cyclase c, method of making and using same
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
AU2015308350B2 (en) 2014-08-29 2020-03-05 Tes Pharma S.R.L. Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
US10743813B2 (en) 2014-09-11 2020-08-18 Rattan Nath Diabetes control using postprandial feedback
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
US11273131B2 (en) 2016-05-05 2022-03-15 Aquestive Therapeutics, Inc. Pharmaceutical compositions with enhanced permeation
KR20190005199A (ko) 2016-05-05 2019-01-15 어퀘스티브 테라퓨틱스, 아이엔씨. 강화된 전달 에프네프린 조성물
WO2018069532A1 (en) 2016-10-14 2018-04-19 Tes Pharma S.R.L. Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
EP3551176A4 (en) 2016-12-06 2020-06-24 Merck Sharp & Dohme Corp. ANTIDIABETIC HETEROCYCLIC COMPOUNDS
EP3558298A4 (en) 2016-12-20 2020-08-05 Merck Sharp & Dohme Corp. ANTIDIABETIC SPIROCHROMAN COMPOUNDS
CN113302189A (zh) 2018-11-20 2021-08-24 Tes制药有限责任公司 α-氨基-β-羧基己二烯二酸半醛去羧酶的抑制剂
EP3911648A4 (en) 2019-01-18 2022-10-26 Astrazeneca AB PCSK9 INHIBITORS AND METHODS OF USE THEREOF
NL2022615B1 (en) 2019-02-21 2020-08-31 Patrick Alexander Unger Pharmaceutical composition comprising tetrahydrocannabivarin for the prevention and treatment of overweight
US20230338387A1 (en) 2020-02-05 2023-10-26 Nof Corporation Agent For Treating Or Preventing Pancreatic Fistula

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS608117B2 (ja) * 1977-02-08 1985-02-28 財団法人微生物化学研究会 新生理活性物質エステラスチンおよびその製造法
GB2023604B (en) * 1978-05-25 1982-07-28 Microbial Chem Res Found Physiologically active derivatives of esterastin and production thereof
JPS56128774A (en) * 1980-03-14 1981-10-08 Microbial Chem Res Found New physiologically active substance ebelactone and its preparation
CA1328881C (en) * 1984-12-21 1994-04-26 Pierre Barbier Process for the manufacture of oxetanones

Also Published As

Publication number Publication date
ES8600650A1 (es) 1985-10-16
IL72122A0 (en) 1984-10-31
PH19704A (en) 1986-06-16
FI78694B (fi) 1989-05-31
JPH0516426B2 (ko) 1993-03-04
NO159941B (no) 1988-11-14
FI78694C (fi) 1989-09-11
CA1247547A (en) 1988-12-28
MC1602A1 (fr) 1985-05-09
LU90302I2 (fr) 1998-12-21
BG60766B2 (bg) 1996-02-29
DK308584A (da) 1984-12-23
KR920002314B1 (ko) 1992-03-21
ES533557A0 (es) 1985-10-16
DK160496C (da) 1991-08-26
DK160496B (da) 1991-03-18
IE841566L (en) 1984-12-22
US4598089A (en) 1986-07-01
NL980029I2 (nl) 1999-06-01
MX9203633A (es) 1992-07-01
NO2000003I1 (no) 2000-05-31
GR82120B (ko) 1984-12-13
DK308584D0 (da) 1984-06-22
FI842422A (fi) 1984-12-23
NL980029I1 (nl) 1999-01-04
PT78777A (en) 1984-07-01
NZ208521A (en) 1988-02-29
PT78777B (en) 1986-09-15
NO842512L (no) 1984-12-27
LV5747B4 (lv) 1996-12-20
IL72122A (en) 1987-07-31
LV5747A4 (lv) 1996-10-20
AU2947884A (en) 1985-01-03
FI842422A0 (fi) 1984-06-14
HU193579B (en) 1987-10-28
JPS6013777A (ja) 1985-01-24
DE3466538D1 (de) 1987-11-05
EP0129748A1 (de) 1985-01-02
DE19875045I2 (de) 2000-01-20
HUT34545A (en) 1985-03-28
IE57761B1 (en) 1993-03-24
AU572851B2 (en) 1988-05-19
ATE30025T1 (de) 1987-10-15
NO159941C (no) 1989-02-22
ZA844558B (en) 1985-02-27
EP0129748B1 (de) 1987-09-30

Similar Documents

Publication Publication Date Title
KR850000530A (ko) 루신 유도체의 제조방법
ATE3059T1 (de) Antibiotikum c-15003 pnd-0 und herstellung von antibiotikum c-15003 pnd.
KR910009729A (ko) 신규한 폴리펩티드 화합물과 그 제조방법
KR840007257A (ko) 레베카마이신과 그것의 제조방법
KR840005483A (ko) A47934 항생물질의 제조방법
KR860001120A (ko) 폴리사이클릭 에테르 항생물질의 제조방법
ES445965A1 (es) Procedimiento para la obtencion de nuevo antibiotico papula-candina.
KR920701455A (ko) 발효에 의한 2-(4-히드록시페녹시)프로피온산의 제조 방법
GB1525977A (en) Aminoglycoside antibiotic complex
KR890014457A (ko) 신규 아족시 화합물 및 그의 제조방법
KR830007831A (ko) 항생물질 a-4696인자 g의 제조방법
KR840005489A (ko) 데(미시노실옥시)틸로신 유도체의 제조방법
KR920018228A (ko) 발효에 의한 l-리신의 제조방법
KR850003730A (ko) 항생물질 x-14889 a, b, c 및 d의 제조방법
KR830006432A (ko) 헤테로 폴리싸카라이드 s-119의 제법
ES2046184T3 (es) Un procedimiento para preparar un compuesto que es antibiotico a 42867 y sus sales por adicion.
KR910014509A (ko) 항생성 알리사마이신, 이의 제조방법 및 용도
KR830005357A (ko) 나라신의 제조방법
KR850006873A (ko) 산성 폴리사이클릭 에테르 항생물질의 제조방법
KR860002574A (ko) 항생물질 at 2433 복합체의 제조방법
KR840008166A (ko) L-클루탐산의 제조방법
KR830002028A (ko) 트리아젠 화합물 및 그 항생제의 제조방법
KR850003160A (ko) 글리코펩타이드 항생물질 cuc/csv의 제조방법
KR890003746A (ko) 항생물질 a80577 및 이의 제조방법
SU794070A1 (ru) Способ получени корма

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20040113

Year of fee payment: 13

EXPY Expiration of term